Published guidelines on the treatment of thyroid carcinoma support TSH suppressive
therapy as the standard of care for long-term follow-up after initial surgery and sequential …

The ideal therapy for differentiated thyroid cancer is uncertain. Although thyroid hormone
treatment is pivotal, the degree of thyrotropin (TSH) suppression that is required to prevent …

Surgery—with or without postoperative radioiodine—is the standard of care for most patients
with differentiated thyroid carcinoma (DTC). Thyroid hormone replacement therapy is the …

Context: TSH suppression therapy has been used to decrease thyroid cancer recurrence.
However, validation of effects through studies providing a high level of evidence has been …

Background: Long-term management of intermediate-and high-risk differentiated thyroid
cancer (DTC) involves thyrotropin (TSH) suppression with thyroid hormone to prevent …

An overview of long-term clinical consequences of TSH suppressive therapy provides
evidence that serum TSH levels should be maintained at levels< 0.1 mU/l in high-risk (stage …

Differentiated thyroid cancer is the most common form of thyroid cancer and its prognosis is
favourable in most cases. Suppression of thyroid stimulating hormone (TSH) by supra …

Background: Despite clinical practice guidelines for the management of differentiated thyroid
cancer (DTC), there are no recommendations on the optimal serum thyrotropin (TSH) …

The rationale behind thyroid hormone suppression therapy is the knowledge that thyroid-
stimulating hormone (TSH), secreted by the pituitary, affects growth and proliferation of …

Background: Current guidelines recommend against thyrotropin (TSH) suppression in low-
risk differentiated thyroid cancer patients; however, physician practices remain …